DadFinStart your free week
DadFin › Stocks › Healthcare › AMLX

Amylyx Pharmaceuticals, Inc. (AMLX) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$28.14 ▲ +3.46% today

6.2
Dad Score, out of 100
poor

Amylyx Pharmaceuticals, Inc. (AMLX) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 6.2 out of 100 on the Dad Score, a poor reading that places the business ahead of 6% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #925 of 974. Its strongest axis is liquidity; its weakest are valuation and quality.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Below average
Growth
Weak
Price action
Average
Risk
Average
Conviction
Average
Liquidity
Above average
Macro
Average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-24.1×
Dividend yield0.00%
Return on capital-46.7%
Operating margin0.0%
Revenue growth (YoY)-100.0%
FCF yield-3.7%
Net debt / EBITDA3.00×
Piotroski F-Score4 / 9
52-week change+119.0%
Market cap$3.5B
Next earningsNov 5, 2026

What subscribers see on AMLX

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.